跳至主要内容
临床试验/DRKS00032547
DRKS00032547已完成Unknown

Evaluation of the Impact of mebix in Patients with Type II Diabetes mellitus in daily practice - EDDYII

niversitätsklinikum Carl Gustav Carus der Technischen Universität Dresden Medizinische Klinik III Abteilung Prävention und Versorgung des Diabetes0 个研究点目标入组 48 人开始时间: 2023年8月24日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Patients = 18 years old
  • Type 2 diabetes patients benefitting from improved self-management
  • Patients using/willing to use a Diabetes DiGA as part of their diabetes management
  • HbA1c at baseline = 7,5 % and = 11.0 %
  • Patients with internet access and a computer and/or smartphone compatible with the Vitadio DiGA
  • Digital literacy to use a smartphone adequately and willing to use it for their diabetes self-management
  • Sufficient understanding of user interface (UI) of the Vitadio DiGA
  • Participants willing and able to comply with all scheduled visits, laboratory tests, lifestyle considerations and other study procedures
  • Participants capable of giving personal informed consent

排除标准

  • Patients using other Apps for their diabetes management
  • Patients who have been using a Diabetes DiGA in the past twelve months
  • Patients with impairments – including mental or psychic impairments – or conditions which, in the opinion of the investigator, would seriously compromise the integrity of the study
  • Patients under 18 years of age
  • Patients participating in a weight loss program in the last 6 months
  • Patients treated with an insulin pump or continuous glucose management (CGM)

研究者

发起方
niversitätsklinikum Carl Gustav Carus der Technischen Universität Dresden Medizinische Klinik III Abteilung Prävention und Versorgung des Diabetes

相似试验

进行中(未招募)
1 期
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-Small Cell Lung Cancer, or Melanoma That Has Spread to the Brai
EUCTR2014-004010-28-ATEli Lilly and Company247
进行中(未招募)
1 期
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer That Has Spread to the BraiBrain tumours, Breast CancerMedDRA version: 18.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864
EUCTR2014-004010-28-FREli Lilly and Company120
进行中(未招募)
1 期
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-Small Cell Lung Cancer, or Melanoma That Has Spread to the Brai
EUCTR2014-004010-28-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER162
进行中(未招募)
1 期
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-Small Cell Lung Cancer, or Melanoma That Has Spread to the BraiBrain tumours, Breast Cancer, Non-Small Cell Lung Cancer, MelanomaMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000020826
EUCTR2014-004010-28-BEEli Lilly and Company251
进行中(未招募)
1 期
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-Small Cell Lung Cancer, or Melanoma That Has Spread to the BraiBrain tumors, Breast CancerMedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864
EUCTR2014-004010-28-ESilly S.A.247